Inflammatory Bowel Disease Treatment Global Market Report 2024

Treatment for inflammatory bowel disease involves the use of anti-inflammatory medications commonly employed for mild to moderate cases of ulcerative colitis. Aminosalicylates, including mesalamine (Delzicol, Rowasa, among others), balsalazide (Colazal), and olsalazine, serve as anti-inflammatories, with Dipentum being one of them.

The primary drug categories in the treatment of inflammatory bowel disease encompass aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and other options. Aminosalicylates, a specific class of drugs, are utilized to manage and prevent flare-ups in ulcerative colitis and Crohn's disease. The mechanism of action of aminosalicylates involves inhibiting the production of cyclo-oxygenase, prostaglandin, thromboxane synthetase, platelet-activating factor synthetase, and interleukin-1 by macrophages. Both orally and via injection, treatments for inflammatory bowel disease are administered for Crohn’s disease and ulcerative colitis. These medications are available through hospital pharmacies, retail pharmacies, and online pharmacies.

The inflammatory bowel disease treatment market research report is one of a series of new reports that provides inflammatory bowel disease treatment market statistics, including inflammatory bowel disease treatment industry global market size, regional shares, competitors with an inflammatory bowel disease treatment market share, detailed inflammatory bowel disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the inflammatory bowel disease treatment industry. This inflammatory bowel disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inflammatory bowel disease treatment market size has grown strongly in recent years. It will grow from $23.49 billion in 2023 to $25.56 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The rise during the historical period can be ascribed to a heightened prevalence of inflammatory bowel disease, a growing need for biologics and immunomodulators, advancements in treatment choices, an expanding geriatric population, and an increased awareness regarding the disease.

The inflammatory bowel disease treatment market size is expected to see strong growth in the next few years. It will grow to $36.63 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The expansion projected for the forecast period can be linked to a surge in investment in research and development activities, a rising demand for biosimilars, an increasing incidence of inflammatory bowel disease in emerging markets, a growing preference for personalized medicine, and the integration of precision medicine in IBD treatment. Key trends expected in the forecast period involve a rise in product launches and approvals, the implementation of personalized dosing and treatment plans in IBD management, the utilization of telemedicine for remote monitoring of IBD patients, exploration of microbiome-based therapies for IBD, and the adoption of value-based care models in IBD treatment.

The significant increase in the prevalence of Crohn’s disease and ulcerative colitis is a key driver for the growth of the market for inflammatory bowel disease treatment. Crohn’s disease and ulcerative colitis, categorized as inflammatory bowel diseases (IBD), involve inflammation and ulcers in the digestive tracts. The growing incidence of these diseases is expected to elevate the demand for treatments that aim to reduce bowel inflammation and prevent medical complications. A March 2022 research publication from the United States National Library of Medicine indicates that approximately 1.6 million Americans presently suffer from inflammatory bowel disease, with around 70,000 new cases diagnosed annually in the USA. Consequently, the increasing prevalence of Crohn's disease and ulcerative colitis is anticipated to propel the growth of the inflammatory bowel disease treatment market.

The rise in the geriatric population is forecasted to drive the growth of the inflammatory bowel disease treatment market in the future. The geriatric population, comprising individuals aged 65 and older, exhibits a higher susceptibility to inflammatory bowel diseases, resulting in an increased demand for treatments and therapies. This demographic shift is expected to contribute to the expansion of the inflammatory bowel disease treatment market. A report from the World Health Organization (WHO) in October 2022 highlights that by the year 2030, one in six people globally is expected to be 60 or older, and by 2050, there will be an estimated 2.1 billion people worldwide aged 60 or older. Thus, the growth of the geriatric population is a significant factor propelling the inflammatory bowel disease treatment market.

Technological advancement is a prominent trend gaining traction in the inflammatory bowel disease treatment market. Key market players are actively adopting technologies like artificial intelligence (AI) in drug discovery processes and introducing advanced treatments for inflammatory bowel diseases. Collaboration between major players and technology firms is a prevalent strategy to leverage their respective strengths and technologies for developing new treatments and enhancing their market position. For example, in May 2021, CytoReason, an Israeli technology start-up specializing in a computational model of the human body, partnered with Ferring Pharmaceuticals, a Switzerland-based multinational pharmaceutical company, to utilize artificial intelligence technology in the drug discovery process for new inflammatory bowel disease treatments. The collaboration combines Ferring's medical expertise with CytoReason's AI technology to create cell-centered disease models, providing critical insights into cellular-level functioning and disease treatment.

Major companies in the inflammatory bowel disease treatment market are focusing on the development of innovative products targeting larger customer bases and increasing revenue. Treatments for moderate to severe active ulcerative colitis, involving medications and sometimes surgical interventions, are a key area of innovation. In October 2023, Eli Lilly and Company, a US-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz), the first interleukin-23p19 (IL-23p19) antagonist designed to treat adults with moderately to severely active ulcerative colitis (UC). Omvoh targets the IL-23 pathway, effectively blocking inflammation associated with UC. The treatment regimen involves initial infusions followed by subcutaneous self-injections during the maintenance phase.

In March 2022, Pfizer, Inc., a U. S. -based pharmaceutical and biotechnology company, acquired Arena Pharmaceuticals, Inc., for $6.7 billion. Through this acquisition, Pfizer aims to enhance its research capabilities in the Inflammation and Immunology therapeutic area, develop therapies for immuno-inflammatory diseases, and continue the clinical development of existing drug candidates. Arena Pharmaceuticals, Inc., is a U. S. -based biopharmaceutical company specializing in the development of novel treatments for various immuno-inflammatory conditions.

Major companies operating in the in the inflammatory bowel disease treatment market report are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Union Chimique Belge S. A., Advanced Gastroenterology and Surgery Associates P. A., Atlanta Gastroenterology Associates LLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cedars-Sinai Medical Center, Celgene Corporation, Cleveland Clinic Foundation, Digestive Disease Associates of Rockland P. C., Eli Lilly and Company, Gastrointestinal Specialists Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Illinois Gastroenterology Group LLC, The Johns Hopkins Hospital Inc., Massachusetts General Hospital, Mayo Clinic, Merck & Co. Inc., Mount Sinai Health System Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Texas Digestive Disease Consultants P. A., The Oregon Clinic - Gastroenterology West P. C., Ebony 60 Inc., Salix Pharmaceuticals Inc., Shire plc, Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc.

North America was the largest region in the inflammatory bowel disease treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the inflammatory bowel disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The inflammatory bowel disease treatment market includes revenues earned by entities by reducing the inflammation that triggers the signs and symptoms. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.